Kukje Pharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 02:56 am EDT
Share
Kukje Pharma Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 35,544.88 million compared to KRW 32,241.18 million a year ago. Net loss was KRW 6,265.53 million compared to net income of KRW 1,187.12 million a year ago. Basic loss per share from continuing operations was KRW 309 compared to basic earnings per share from continuing operations of KRW 59 a year ago. Diluted loss per share from continuing operations was KRW 309 compared to diluted earnings per share from continuing operations of KRW 59 a year ago. Basic loss per share was KRW 309 compared to basic earnings per share of KRW 59 a year ago.
For the six months, sales was KRW 67,952.61 million compared to KRW 65,491.94 million a year ago. Net loss was KRW 5,432.23 million compared to net income of KRW 3,333.65 million a year ago. Basic loss per share from continuing operations was KRW 268 compared to basic earnings per share from continuing operations of KRW 165 a year ago. Diluted loss per share from continuing operations was KRW 268 compared to diluted earnings per share from continuing operations of KRW 165 a year ago. Basic loss per share was KRW 268 compared to basic earnings per share of KRW 165 a year ago.
Kukje Pharma Co., Ltd, formerly Kukje Pharma Ind. Co., Ltd, is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products are finished products, such as antibiotics, other antibiotics for injection, antifungal and antiviral agents, agents for gastrointestinal tract and liver, muscle relaxants, anti-osteoporotics, corticosteroids, agents for cardiovascular and endocrine systems, ophthalmic agents, remedies for central nervous system (CNS) disorders, remedies for urinary systems, antihistamines, antitussives, cough and cold remedies, non-steroidal anti inflammatory drugs (NSAIDs), antitussive, cough and cold remedies, as well as other over-the-counter (OTC) drugs. It also provides raw materials, such as ceftriaxone sodium sterile, cefuroxime axetil, ceftezole sodium sterile, cefminox sodium sterile, cefuroxime sodium sterile and others.